AFJK Stock Forecast: Aimei Health Technology Co., Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 1 Aug 2026 — in the upper half.
AFJK stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Aimei Health Technology Co., Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
The rank is the raw material. Whether the rules would actually own Aimei Health Technology Co., Ltd. — and when they’d sell — is the membership.
AFJK stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AFJK, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AFJK analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Aimei Health Technology Co., Ltd. (AFJK) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 80.3×
- Price / sales
- —
- Price / book
- 4.7×
- EV / EBITDA
- −48.1×
Cheaper than 9% of US stocks
Cheaper than 22% of US stocks
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −75.4%
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 5% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 13.2%
- Return on assets
- −1.1%
- Dividend yield
- —
Higher than 72% of US stocks
Higher than 39% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AFJK vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| AFJKAimei Health Technology Co., Ltd. | $38.1M | 72 |
| RDACRising Dragon Acquisition Corp. | $39.3M | 63 |
| DTSQDT Cloud Star Acquisition Corp. | $41.4M | 91 |
| QETAQuetta Acquisition Corp. | $44.0M | 35 |
| PGACPantages Capital Acquisition Corp. | $31.8M | 58 |
| YHNAYHN Acquisition I Ltd. | $46.9M | 74 |
| COLAColumbus Acquisition Corp. | $48.0M | 69 |
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AFJK appears on the weeks it earns a place.
Frequently asked questions about AFJK stock
How does Ticker Nerd's model rank AFJK?
As at 1 Aug 2026, Aimei Health Technology Co., Ltd. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
What is the AFJK stock forecast for 2030?
No analyst covering Aimei Health Technology Co., Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AFJK are extrapolating price history, which says nothing about the business.
What does Aimei Health Technology Co., Ltd. do?
Aimei Health Technology Co., Ltd. is a blank check company, also known as a special purpose acquisition company (SPAC), incorporated in 2023 and headquartered in New York, NY.
About Aimei Health Technology Co., Ltd.
Aimei Health Technology Co., Ltd. is a blank check company, also known as a special purpose acquisition company (SPAC), incorporated in 2023 and headquartered in New York, NY. It has no significant operations of its own and exists primarily to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company focuses on opportunities in healthcare-related sectors, including biopharmaceuticals, medical technology and devices, diagnostics, and other services, though it remains open to targets across industries and geographies. Currently, it has entered into a definitive business combination agreement with United Hydrogen Group Inc. and related entities to form United Hydrogen Global Inc. as the combined public entity through a series of mergers. Aimei Health Technology Co., Ltd. raises capital via its initial public offering, holds proceeds in a trust account for public shareholders, and pursues completion of the transaction within an extendable timeframe, subject to shareholder approvals, redemptions, and regulatory conditions. Classified in the financial services sector as a shell company, it plays a key role in facilitating public market access for private businesses via the SPAC structure.
CEO Mr. Junheng Xie · United States